Cargando…

Respiratory Syncytial Virus Hospitalizations in Healthy Preterm Infants: Systematic Review

BACKGROUND: Studies have explored the risk for and impact of respiratory syncytial virus (RSV) infection requiring hospitalization among healthy preterm infants born at 29–35 weeks of gestational age not given RSV immunoprophylaxis. We performed a systematic review and qualitative synthesis of these...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mauskopf, Josephine, Margulis, Andrea V., Samuel, Miny, Lohr, Kathleen N.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Williams & Wilkins 2016
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4927309/ https://www.ncbi.nlm.nih.gov/pubmed/27093166 http://dx.doi.org/10.1097/INF.0000000000001163

Ejemplares similares

Chronologic Age at Hospitalization for Respiratory Syncytial Virus Among Preterm and Term Infants in the United States
por: Parikh, Rohan C., et al.
Publicado: (2017)

Risk Factors for RSV Hospitalization in Healthy Preterm Infants: A Meta-analysis
por: Abeysinghe, Shaun, et al.
Publicado: (2017)

Systematic Literature Review of Risk Factors for Poor Outcomes Among Adults With Respiratory Syncytial Virus Infection in High-Income Countries
por: Njue, Annete, et al.
Publicado: (2023)

Epidemiology of Respiratory Syncytial Virus Infection in Preterm Infants
por: Resch, Bernhard, et al.
Publicado: (2011)

Respiratory syncytial virus hospitalization outcomes and costs of full-term and preterm infants
por: McLaurin, K K, et al.
Publicado: (2016)

Impact of Respiratory Syncytial Virus–Confirmed Hospitalizations on Caregivers of US Preterm Infants
por: Pokrzywinski, Robin M., et al.
Publicado: (2019)

Long-Term Burden and Respiratory Effects of Respiratory Syncytial Virus Hospitalization in Preterm Infants—The SPRING Study
por: Carbonell-Estrany, Xavier, et al.
Publicado: (2015)

Detection of respiratory syncytial virus and rhinovirus in healthy infants
por: Hasegawa, Kohei, et al.
Publicado: (2015)

The epidemiology of medically attended respiratory syncytial virus in older adults in the United States: A systematic review
por: Colosia, Ann D., et al.
Publicado: (2017)

Respiratory syncytial virus acute respiratory infection‐associated hospitalizations in preterm Mexican infants: A cohort study
por: Benítez‐Guerra, Daniela, et al.
Publicado: (2020)

Assessing Variation in the Cost of Palivizumab for Respiratory Syncytial Virus Prevention in Preterm Infants
por: Shahabi, Ahva, et al.
Publicado: (2017)

Suptavumab for the Prevention of Medically Attended Respiratory Syncytial Virus Infection in Preterm Infants
por: Simões, Eric A F, et al.
Publicado: (2020)

Seasonal peaks and risk factors of respiratory syncytial virus infections related hospitalization of preterm infants in Taiwan
por: Chi, Hsin, et al.
Publicado: (2018)

Effectiveness of palivizumab immunoprophylaxis in preterm infants against respiratory syncytial virus disease in Qatar
por: Abushahin, Ahmad, et al.
Publicado: (2018)

Comparison of risk factors between preterm and term infants hospitalized for severe respiratory syncytial virus in the Russian Federation
por: Gooch, Katherine L, et al.
Publicado: (2011)

1413. Trends in Risk of Respiratory Syncytial Virus Hospitalizations in Preterm Infants Over a 10-Year Period
por: Kong, Amanda M, et al.
Publicado: (2020)

Hospitalizations for respiratory syncytial virus bronchiolitis in preterm infants at <33 weeks gestation without bronchopulmonary dysplasia: the CASTOR study
por: GOUYON, J.-B., et al.
Publicado: (2013)

Respiratory syncytial virus hospitalizations in US preterm infants after the 2014 change in immunoprophylaxis guidance by the American Academy of Pediatrics
por: Krilov, Leonard R., et al.
Publicado: (2020)

Prolonged Seasonality of Respiratory Syncytial Virus Infection among Preterm Infants in a Subtropical Climate
por: Hsu, Chyong-Hsin, et al.
Publicado: (2014)

Cost-effectiveness of rule-based immunoprophylaxis against respiratory syncytial virus infections in preterm infants
por: Blanken, Maarten O., et al.
Publicado: (2017)

IFI27 may predict and evaluate the severity of respiratory syncytial virus infection in preterm infants
por: Gao, Junyan, et al.
Publicado: (2021)

Respiratory syncytial virus in severe lower respiratory infections in previously healthy young Ethiopian infants
por: Weldetsadik, Abate Yeshidinber, et al.
Publicado: (2021)

Treatment Sequencing After Failure of the First Biologic in Cost-Effectiveness Models of Psoriasis: A Systematic Review of Published Models and Clinical Practice Guidelines
por: Mauskopf, Josephine, et al.
Publicado: (2014)

The disease burden of respiratory syncytial virus in Infants
por: Munro, Alasdair P.S., et al.
Publicado: (2023)

2353. Respiratory Syncytial Virus (RSV) in Preterm Infants: Epidemiology, Clinical Pattern, and Risk Factors in a Pediatric Hospital in Argentina
por: Gentile, Angela, et al.
Publicado: (2018)

Evaluation of recent New Vaccine Surveillance Network data regarding respiratory syncytial virus hospitalization rates in US preterm infants
por: DeVincenzo, John P., et al.
Publicado: (2016)

Respiratory Syncytial Virus and All-Cause Bronchiolitis Hospitalizations Among Preterm Infants Using the Pediatric Health Information System (PHIS)
por: Fergie, Jaime, et al.
Publicado: (2020)

Respiratory Syncytial Virus Disease: Immunoprophylaxis Policy Review and Public Health Concerns in Preterm and Young Infants
por: Staebler, Suzanne, et al.
Publicado: (2020)

RESPIRATORY SYNCYTIAL AND OTHER VIRUSES ASSOCIATED WITH RESPIRATORY DISEASE IN INFANTS
por: Jacobs, J.W., et al.
Publicado: (1971)

Utilization Management Opportunities for Palivizumab for Prophylaxis of Respiratory Syncytial Virus Complications in Infants
por: Curtiss, Frederic R., et al.
Publicado: (2010)

Evaluation of viral load in infants hospitalized with bronchiolitis caused by respiratory syncytial virus
por: Scagnolari, Carolina, et al.
Publicado: (2012)

Respiratory Syncytial Virus Disease in Preterm Infants in the US Born at 32–35 Weeks Gestation Not Receiving Immunoprophylaxis
por: Ambrose, Christopher S., et al.
Publicado: (2014)

Respiratory syncytial virus associated hospitalizations in preterm infants of 29 to 32 weeks gestational age using a risk score tool for palivizumab prophylaxis
por: Resch, B., et al.
Publicado: (2017)

Respiratory Syncytial Virus Infection in High-Risk Infants
por: Resch, Bernhard
Publicado: (2011)

Respiratory syncytial virus infection in infants in rural Nepal
por: Chu, Helen Y., et al.
Publicado: (2016)

2616. Genetic Susceptibility to Life-Threatening Respiratory Syncytial Virus Infection in Previously Healthy Infants
por: Ferolla, Fausto Martin, et al.
Publicado: (2019)

735. Severity and Healthcare Costs of Respiratory Syncytial Virus Hospitalizations in US Preterm Infants Born at 29–34 Weeks Gestation: 2014–2016
por: Goldstein, Mitchell, et al.
Publicado: (2018)

Population-based trends and underlying risk factors for infant respiratory syncytial virus and bronchiolitis hospitalizations
por: Bennett, Mihoko V., et al.
Publicado: (2018)

Respiratory Syncytial Virus Hospitalizations among U.S. Preterm Infants Compared with Term Infants Before and After the 2014 American Academy of Pediatrics Guidance on Immunoprophylaxis: 2012–2016
por: Goldstein, Mitchell, et al.
Publicado: (2018)

Respiratory Syncytial Virus–Associated Hospitalization Rates among US Infants: A Systematic Review and Meta-Analysis
por: McLaughlin, John M, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_2nce8l78o5tvdb5s5b4ltcrdjb